## Carla Abdelnour

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6050173/publications.pdf

Version: 2024-02-01

28 papers

886

<sup>394421</sup>

19

h-index

27 g-index

28 all docs 28 docs citations

28 times ranked

1643 citing authors

#	Article	IF	CITATIONS
1	Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimer's Research and Therapy, 2018, 10, 12.	6.2	72
2	Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Movement Disorders, 2016, 31, 1203-1208.	3.9	70
3	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. Journal of Alzheimer's Disease, 2017, 57, 787-795.	2.6	69
4	Challenges for Service Robotsâ€"Requirements of Elderly Adults with Cognitive Impairments. Frontiers in Neurology, 2017, 8, 228.	2.4	62
5	$\hat{l}^2$ -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.1	62
6	GBA and APOE $\hat{l}\mu 4$ associate with sporadic dementia with Lewy bodies in European genome wide association study. Scientific Reports, 2019, 9, 7013.	3.3	53
7	Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. Scientific Reports, 2018, 8, 16345.	3.3	52
8	Influence of Sampling and Recruitment Methods in Studies of Subjective CognitiveÂDecline. Journal of Alzheimer's Disease, 2015, 48, S99-S107.	2.6	40
9	The Role of Verb Fluency in the Detection of Early Cognitive Impairment inÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 611-619.	2.6	39
10	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2022, 79, 32.	9.0	38
11	Exploring <i>APOE</i> genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. Alzheimer's and Dementia, 2018, 14, 634-643.	0.8	33
12	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Scientific Reports, 2019, 9, 8698.	3.3	32
13	Concordance between Subjective and Objective Memory Impairment in Volunteer Subjects. Journal of Alzheimer's Disease, 2015, 48, 1109-1117.	2.6	30
14	The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. Scientific Reports, 2018, 8, 3828.	3.3	28
15	Impact of Recruitment Methods in Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2017, 57, 625-632.	2.6	26
16	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 25.	6.2	24
17	Association between retinal thickness and $\hat{l}^2$ -amyloid brain accumulation in individuals with subjective cognitive decline: Fundaci $\tilde{A}^3$ ACE Healthy Brain Initiative. Alzheimer's Research and Therapy, 2020, 12, 37.	6.2	24
18	The combined effect of amyloid- $\hat{l}^2$ and tau biomarkers on brain atrophy in dementia with Lewy bodies. Neurolmage: Clinical, 2020, 27, 102333.	2.7	22

#	Article	IF	CITATIONS
19	Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. Scientific Reports, 2020, 10, 1580.	3.3	22
20	Patient Engagement: The Fundaci $\tilde{A}^3$ ACE Framework for Improving Recruitment and Retention in Alzheimer $\hat{a} \in \mathbb{R}^3$ Disease Research. Journal of Alzheimer's Disease, 2018, 62, 1079-1090.	2.6	20
21	The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening. Alzheimer's Research and Therapy, 2021, 13, 95.	6.2	13
22	Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	3.4	12
23	From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery. Journal of Alzheimer's Disease, 2021, 81, 1541-1553.	2.6	11
24	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimer's Research and Therapy, 2022, 14, 14.	6.2	10
25	Social Representation of Dementia: An Analysis of 5,792 Consecutive Cases Evaluated in a Memory Clinic. Journal of Alzheimer's Disease, 2017, 58, 1099-1108.	2.6	9
26	CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 109-110.	1.9	8
27	Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort. Scientific Reports, 2020, 10, 17721.	3.3	5
28	Sex and gender considerations in clinical trials for Alzheimer's disease: Current state and recommendations. , 2021, , 309-327.		0